See how pharmaceutical companies balance the cost-effectiveness of anticancer drugs

[market analysis of chinapharma.com] in the United States, the cost of bringing a new anti-cancer drug to the market is extremely high, but pharmaceutical companies often expand their product benefits by listing multiple indications According to the research report from best practices, although most (60%) of the 20 drugs on the market fail to meet the initial sales expectations after the first indications on the market, these drugs can often obtain significant benefits through the subsequent approval and marketing of the second or third treatment indications The average investment in the operation of indications listed products is 13 million US dollars, and the average large amount of this expenditure in 12 pharmaceutical companies is 20 million US dollars, including Pfizer, Amgen, Bayer, Novartis and Lilly Best practices analyzed 17 different marketing cost areas and found that 8 of them could improve the product efficiency at least 20% by listing the second or more indications In the field of patient service, 50% of the benefits are improved In the field of non personal promotion and digital non personal promotion, the average cost can be reduced by 30% The other five marketing areas include patient assistance, sales recruitment and training, non brand education, samples and DTC spending It's great for pharmaceutical companies to be able to expand their product indications All pharmaceutical companies will strive to expand the indications According to the research report, 40% of them will expand the indications of their products to four, and another 60% will choose to increase the indications to at least three or more Cameron TEW, head of research services and business operations at best practices, said: "nowadays, the pressure of product pricing and drug payment is getting higher and higher, so cost awareness has to be taken seriously What we are discussing here is not in the scope of daily lifestyle diseases such as erectile dysfunction and acne, but some of the major life-threatening diseases In the field of disease, but pharmaceutical companies still need to consider cost, which is part of the reason why pharmaceutical companies have been looking for higher cost-effectiveness " Anticancer drugs also have lower expected peak sales 15 drugs in the research report did not reach the peak of $1 billion, which makes cost awareness more urgent "Pharmaceutical companies have to take into account the duplication of work in the market (such as interaction with agents, drug payment agencies, doctor groups) and figure out how you will save costs in these areas," TEW said According to the research report, most pharmaceutical companies will seek multiple indications of anti-cancer drugs and actively promote them, but will promote each indication as a separate brand, and allocate independent brand managers and supporting sales information The idea of multi indication marketing, promotion and cost-benefit analysis is not only in cancer, but also in other areas such as rare diseases and immune diseases For example, the indications of Humira, a drug of Alberta, have included rheumatoid arthritis, intestinal diseases (GI) and skin diseases TEW pointed out that the reason why Sumeria became a global drug was not the indications of the product, but the subsequent marketing indications.